A 30 year old female had a breast lesion of 1.2×1 cm, underwent lumpectomy with positive axillary nodes. And she was taking adjuvant radiotherapy with tamoxifen and chemotherapy, which is the line of management for her?
**Core Concept**
The management of breast cancer involves a multidisciplinary approach, including surgery, radiotherapy, hormone therapy, and chemotherapy, tailored to the individual patient's stage, tumor characteristics, and risk factors. In this case, the patient has undergone lumpectomy with positive axillary nodes, indicating a need for adjuvant therapy to reduce the risk of recurrence.
**Why the Correct Answer is Right**
The patient is receiving tamoxifen, a selective estrogen receptor modulator (SERM), which is effective in reducing the risk of recurrence in estrogen receptor-positive (ER+) breast cancer. Tamoxifen acts by binding to estrogen receptors on cancer cells, thereby inhibiting the growth-promoting effects of estrogen. The patient is also receiving chemotherapy, which targets rapidly dividing cancer cells. Radiotherapy is being used to eliminate any remaining cancer cells in the breast and axilla. Given the patient's ER+ status and positive axillary nodes, this combination of tamoxifen, chemotherapy, and radiotherapy is a standard approach for adjuvant therapy.
**Why Each Wrong Option is Incorrect**
**Option A:** This option might suggest a more aggressive approach, such as mastectomy or more intensive chemotherapy, which may not be necessary in this case given the patient's small tumor size and positive response to lumpectomy and adjuvant therapy.
**Option B:** This option may imply a lack of hormone therapy, which is crucial for patients with ER+ breast cancer, given the patient's tumor characteristics.
**Option C:** This option might suggest a less aggressive approach, such as no adjuvant therapy, which may not be sufficient to reduce the risk of recurrence in this patient.
**Clinical Pearl / High-Yield Fact**
Tamoxifen is a critical component of adjuvant therapy for ER+ breast cancer, and its use has been shown to reduce the risk of recurrence by approximately 50% in high-risk patients.
**Correct Answer:** C.